ONCOSEC MEDICAL Inc

Form 4

December 16, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0287 Number:

OMB APPROVAL

January 31, Expires: 2005

0.5

Estimated average burden hours per response...

Check this box if no longer subject to

may continue.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or Form 5 obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

SECURITIES

See Instruction

(Middle)

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * **DHILLON PUNIT**

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

ONCOSEC MEDICAL Inc [ONCS]

(Check all applicable)

5820 NANCY RIDGE DRIVE

(First)

(Street)

3. Date of Earliest Transaction (Month/Day/Year)

12/14/2016

_X__ Director 10% Owner X_ Officer (give title Other (specify

below) below) President and CEO

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

SAN DIEGO, CA 92121

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following

Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial

Ownership (I) (Instr. 4) (Instr. 4)

(A)

Transaction(s) (Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

Conversion or Exercise

3. Transaction Date 3A. Deemed

(Month/Day/Year) Execution Date, if any

4. 5. Number of TransactionDerivative Securities Code Acquired (A) or

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and Underlying (Instr. 3 an

Edgar Filing: ONCOSEC MEDICAL Inc - Form 4

(Instr. 3)	Price of Derivative		(Month/Day/Year)	(Instr. 8)	Disposed of (Instr. 3, 4,				
	Security			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Employee Stock Option (right to buy)	\$ 4.2	12/14/2016		D		25,000	(2)	04/25/2022	Commor Stock
Employee Stock Option (right to buy)	\$ 4.6	12/14/2016		D		12,500	<u>(4)</u>	02/08/2023	Common Stock
Non-qualified Stock Option (right to buy)	\$ 16.1	12/14/2016		D		100,000	<u>(6)</u>	03/07/2024	Commor Stock
Employee Stock Option (right to buy)	\$ 7.6	12/14/2016		D		25,000	<u>(7)</u>	03/03/2025	Commor Stock
Employee Stock Option (right to buy)	\$ 5.76	12/14/2016		D		500,000	<u>(8)</u>	08/21/2025	Commor Stock
Employee Stock Option (right to buy)	\$ 1.29	12/14/2016		A	314,583		<u>(9)</u>	12/14/2026	Commor Stock

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
DHILLON PUNIT 5820 NANCY RIDGE DRIVE SAN DIEGO, CA 92121	X		President and CEO			
••						

Signatures

/s/ Punit Dhillon	12/16/2016		
**Signature of Reporting Person	Date		

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These stock options were granted as Incentive Stock Options only to the extent that the \$100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option.
- (2) The stock options were scheduled to fully vest on April 25, 2015, the third anniversary of the grant date.
 - On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 25000 shares (previously granted on April 25, 2012), 12500 shares (previously
- granted on February 8, 2013), 100000 shares (previously granted on March 7, 2014), 25000 shares (previously granted on March 3, 2015), and 500000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 314583 shares of common stock with an exercise price of \$1.29 per share.
- (4) The stock options were scheduled to fully vest on February 8, 2016, the third anniversary of the grant date.
- (5) These stock options were granted as Non-qualified stock options.
- (6) The stock options were scheduled to fully vest on March 7, 2017, the third anniversary of the grant date.
- (7) The stock options were scheduled to fully vest on March 3, 2018, the third anniversary of the grant date.
- (8) The stock options were scheduled to fully vest on August 21, 2018, the third anniversary of the grant date.
- The stock options granted on December 14, 2016 will vest on the following schedule: 25% vested on the grant date; 1/36th of the remaining 75% will vest on each of the 36 subsequent monthly anniversaries of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.